Redx Pharma is a drug discovery and development company formed in 2010. It is focused on improving the characteristics of existing drug classes to create best-in-class new drugs in the areas of cancer, infection and autoimmune disease. The company's work has been endorsed by partnerships with global pharmaceutical companies and the NHS.

Find out more


Latest News

Pre-clinical profile of Porcupine inhibitor RXC004 presented at EORTC-NCI-AACR 2016
30 November 2016

preview image of Redx Pharma Novel Porcupine inhibitor RXC004 poster

Redx Pharma is pleased to announce that it will present the pre-clinical profile of its Porcupine inhibitor RXC004 at the 28th European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) Symposium in Munich, Germany, on 30 November 2016.

Redx's Porcupine inhibitor RXC004 exhibits potent and selective inhibition of the Wnt pathway in in vitro and in vivo models of Wnt dependant pancreatic cancer.

Read more

In The Media

19 September 2016
Redx tipped to triple…

Interactive Investor

11 September 2016
Redx Pharma could soar as new drugs come on stream…

Daily Mail Midas Share Tip

6 September 2016
Redx breakthrough cancer drug remains on track…

ProactiveInvestors.co.uk


Our Subsidiary Companies

Discovering and developing new therapeutics in the area of infectious disease generating a pipeline of novel antibacterial & antiviral drugs.

View details

Modulating the immune system with novel small molecules to treat a range of diseases with high unmet medical need.

View details

Delivering multiple development candidates across a range of mechanistic approaches in cancer treatment.

View details